Fluid Biopsy for the Diagnosis of Lung Cancer
This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung cancer. Studying blood samples in the laboratory may help doctors develop a blood test for lung cancer in the future and provide a better way to screen patients for lung cancer.
Checked against the public recordLast updated Sep 5, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Southern California
- Interventions being studied
- Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis; Procedure: Liquid Biopsy; Other: Medical Chart Review
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Scheduled to undergo a diagnostic biopsy for possible lung cancer or * Completed a diagnostic lung cancer biopsy in the prior 2 weeks and has not yet undergone treatment or * Planning or completed in the last 2 weeks a CT lung cancer screen * Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study * Known other solid tumor malignancy other than lung cancer requiring ongoing active treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Los Angeles County-USC Medical CenterLos Angeles, California
- USC / Norris Comprehensive Cancer CenterLos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 5, 2025. Always confirm current availability with the study team.